Influenza-A-virus-H1N1-vaccine - Codagenix
Alternative Names: CODA-VAX H1N1; CodaVax; CodaVax™-H1N1; H1N1 live-attenuated influenza vaccine - CodagenixLatest Information Update: 28 May 2025
At a glance
- Originator Codagenix
- Class Influenza A virus H1N1 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza virus infections
Most Recent Events
- 28 May 2025 No recent reports of development identified for phase-I development in Influenza-virus-infections(Prevention) in Australia (IM, Injection)
- 09 Feb 2024 Codagenix completes a phase I trial in Influenza virus infections (Prevention) in Australia (IM, Injection) (NCT05223179)
- 28 Jul 2022 No recent reports of development identified for phase-I development in Influenza-virus-infections(Prevention) in Australia (Intranasal, Spray)